Bikbov, Mukharram M.
Kazakbaeva, Gyulli M.
Rakhimova, Ellina M.
Rusakova, Iuliia A.
Fakhretdinova, Albina A.
Tuliakova, Azaliia M.
Panda-Jonas, Songhomitra
Gilmanshin, Timur R.
Zainullin, Rinat M.
Bolshakova, Natalia I.
Safiullina, Kamilia R.
Gizzatov, Ainur V.
Ponomarev, Ildar P.
Yakupova, Dilya F.
Baymukhametov, Nail E.
Nikitin, Nikolay A.
Jonas, Jost B.
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
Received: 14 April 2021
Accepted: 2 September 2021
First Online: 16 September 2021
Competing interests
: Jost B. Jonas: Advisory Board Novartis; Patent holder with Biocompatibles UK Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and Europäische Patentanmeldung 16 720 043.5 “Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia”; Advisor board member Abyss Processing Co.. Songhomitra Panda-Jonas: Patent holder with Biocompatibles UK Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and Europäische Patentanmeldung 16 720 043.5 “Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia”. All other authors: No financial disclosures.